Onkologie. 2013:7(5):221-224

Breast cancer in older women

Jana Hornová, Tomáš Büchler
Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

Breast cancer is one of the most common malignancies of the elderly. Despite that, only limited number of studies provide evidence base

for decision-making in elderly patients with breast carcinoma in everyday clinical practice. The article provides an overview of current

knowledge and recommendations for clinical management of this patient population.

Keywords: breast cancer, elderly, chemotherapy, hormonal therapy, radiotherapy

Published: November 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hornová J, Büchler T. Breast cancer in older women. Onkologie. 2013;7(5):221-224.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bastiaannet E, Liefers GJ, de Craen AJ, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127 805 unselected patients. Breast Cancer Res Treat. 2010; 124(3): 801-807. Go to original source... Go to PubMed...
    2. EHEMU - European Health Expectancy Monitoring Unit. Dostupný z WWW: www.ehemu.eu (přístup 25. 7. 2013).
    3. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], Dostupný z WWW: http://www.svod.cz. (přístup 25. 7. 2013).
    4. Eaker S, Dickman PW, Bergkvist L, et al. Uppsala/Orebro Breast Cancer Group. Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med 2006; 3: e25. Go to original source... Go to PubMed...
    5. Büchler T, Hornová J, Kordíková D, et al. Karcinom prsu u žen v pokročilém věku. Prakt. Lék. 2010; 90(1): 40-42.
    6. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000; 92: 550-556. Go to original source... Go to PubMed...
    7. Parks RM, Lakshmanan R, Winterbottom L, et al. Comprehensive geriatric assessment for older women with early breast cancer - a systematic review of literature. J Surg Oncol. 2012; 10: 88. Go to original source... Go to PubMed...
    8. Audisio RA, Bozzetti F, Gennari R, et al. The surgical management of elderly cancer patients: recommendations of the SIOG surgical task force. Eur J Cancer. 2004, 40: 926. Go to original source... Go to PubMed...
    9. Smith BD, Gross CP, Smith GL, et al. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst. 2006; 98(10): 681-690. 25. Go to original source... Go to PubMed...
    10. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25(22): 3259-3265. Go to original source... Go to PubMed...
    11. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. JClin Oncol. 2007, 25: 3808. Go to original source... Go to PubMed...
    12. Jones S, Holmes FA, O'Shaughnessy J. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of U.S. Oncology Research Trial 9735. J Clin Oncol. 2009; 27: 1177-1183. Go to original source... Go to PubMed...
    13. Lichtman SM, Hurria A, Cirrincione CT, et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840 Annals of Oncology 2011; 23(3): 632-638.
    14. Crivellari D, Spazzapan S, Puglisi F, et al. Hormone therapy in elderly breast cancer patients with comorbidities. Crit Rev Oncol Hematol. 2010; 73(1): 92-98. Go to original source... Go to PubMed...
    15. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381(9869): 805-816. Go to original source... Go to PubMed...
    16. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000; 18: 1709-1717. Go to original source... Go to PubMed...
    17. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010; 28: 509. Go to original source... Go to PubMed...
    18. Serrano C, Cortés J, De Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2012; 23(4): 897-902. Go to original source... Go to PubMed...
    19. Johnston SJ, Kenny FS, Syed BM, et al. A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Ann Oncol. 2012; 23(9): 2296-2300. Go to original source... Go to PubMed...
    20. Calle R, Pilleron JP, Schlienger P, Vilcoq JR.Conservative management of operable breast cancer: ten years experience at the Foundation Curie. Cancer 1978; 42(4): 2045-2053. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.